Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15015937 | 1.00 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3UCHL1 | |
| SCHEMBL4120182 | 1.00 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3UCHL1 | |
| SCHEMBL650034 | 0.90 | GPR119 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3UCHL1 | |
| SCHEMBL650737 | 0.90 | GPR119 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3UCHL1 | |
| SCHEMBL2065859 | 0.85 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3USP30 | |
| SCHEMBL2065863 | 0.85 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3USP30 | |
| SCHEMBL4118031 | 0.84 | NR1H2 (0.40) | NR1H2NR1H3GPR119ARSPR | |
| SCHEMBL652254 | 0.84 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| SCHEMBL25966372 | 0.83 | NR1H2 (0.51) | USP30NR1H2NR1H3GPR119AR | |
| SCHEMBL929271 | 0.82 | NR1H2 (0.44) | NR1H2NR1H3GPR119AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231672-B1 | BIARYL SUBSTITUTED DIAZABICYCLOHEPTANE DERIVATIVES AS nAChR MODULATORS | ABBVIE INC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2604611-A1 | N-Biaryl substituted diazabicycloalkane derivatives as agonists of the alpha7 and alpha4beta2 nACh Receptor | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20090197860-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197860-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | BRCA1, VHL, AADAC | CHRNB2 3338/4885CHRNA4 3801/4885CHRNB4 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.